Is AEON or AGMB more undervalued in 2026?

CirclFi compares AEON Biopharma, Inc. (AEON) and AgomAb Therapeutics NV (AGMB) using 13 institutional-grade valuation models. AEON has a Quality of Company score of 3.3/10 while AGMB scores 1.8/10.

Which is a better buy — AEON or AGMB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AEON and AGMB valuations compare?

AEON at $0.72 and AGMB at $11.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AEON vs AGMB Valuation Comparison 2026 — Intrinsic Value Analysis

AEON

Biotechnology

AEON Biopharma, Inc.

Quality

3.3

out of 10

Value Trap

SAFE

Price

$0.72

Last close

Models

7/13

Active

AGMB

Biotechnology

AgomAb Therapeutics NV

Quality

1.8

out of 10

Value Trap

—

Price

$11.54

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	AEON Fair Value	AEON Upside	AGMB Fair Value	AGMB Upside
Bayesian DCF	Intrinsic	$0.12	-86.6%	$3.06	-73.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.02	-97.6%	$8.88	-23.1%
PWERM	Option-Based	$0.99	+38.3%	$13.95	+20.9%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AEON vs AGMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AEON vs AGMB — Which Stock Is More Undervalued?

AEON scores higher with a 3.3/10 quality rating vs AGMB's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AEON Biopharma, Inc. (AEON) and AgomAb Therapeutics NV (AGMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AEON currently trades at $0.72 with a QOC of 3.3/10, while AGMB trades at $11.54 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).